In the popular imagination, drug discovery is often viewed as a moment of sudden inspiration—a "Eureka!" instant where a scientist stumbles upon a cure. In reality, it is a grueling, high-stakes marathon characterized by high attrition rates and soaring costs. At the heart of this complex odyssey lies pharmacology: the science of how drugs interact with living organisms.
References available upon request. For further reading, consult "Goodman & Gilman's The Pharmacological Basis of Therapeutics" and the FDA's "Guidance for Industry: Clinical Pharmacology." pharmacology in drug discovery and development
Pharmacology begins long before synthesis. Using knowledge of disease pathology, pharmacologists identify biological targets—usually proteins, receptors, enzymes, or ion channels—that are implicated in a disease state. For example, in hypertension, the angiotensin-converting enzyme (ACE) is a validated target. However, a target is just a theory until validated. Pharmacologists use techniques like CRISPR gene editing or antisense oligonucleotides to "turn off" the target. If turning off the target alleviates the disease phenotype in cell cultures or animal models, the target is "validated." The Bridge to Medicine: The Central Role of
Drug discovery is often compared to finding a needle in a haystack. Chemistry builds the magnet; biology identifies the haystack; but pharmacology is the hand that guides the magnet to the needle. Attrition rates : The vast majority of compounds